R. Lor Randall, M.D., F.A.C.S.
Professor
Director of Sarcoma Service, Huntsman Cancer Institute
Specialty:Sarcoma/Musculoskeletal Oncology and Orthopaedic Pediatrics
Medical School: Yale University
Residency: University of California,San Francisco
Fellowship: University of Washington
Dr. Randall is the Director of Huntsman Cancer Institutes' Sarcoma Service. His medical education was performed at Yale University and his residency in Orthopaedic surgery at the University of California, San Francisco. A fellowship in musculoskeletal oncology was completed at the University of Washington under Ernest U. Conrad, III. He specializes in the management of both benign and malignant neoplastic conditions of bone and soft tissue in children and adults. In addition to staffing University Hospital and Primary Children's Medical Center, Dr. Randall collaborates with physicians at the Shriners Hospital for Children - Intermountain. He works closely with members of the Huntsman Cancer Institute investigating molecular mechanisms of sarcomagenesis. The Sarcoma Service at the Huntsman Cancer Institute/University of Utah is a comprehensive, interdisciplinary clinical service with an infrastructure in molecular oncology research.
Current Publications
Joyner DE, Aboulafia AJ, Damron TA, Randall RL. Fas Death Pathway in Sarcomas Responds to Epidermal Growth Factor Transcription. Clinical Orthopaedics and Related Research. In press. [abstract]
Malay H, Randall RL, Capecchi M. The Genetics of Synovial Sarcoma: Insights from a mouse model. Clinical Orthopaedics and Related Research. In press. [abstract]
Chen LL, Holden JA, Choi H, Zhu J, Wu EF, Jones KA, Ward JH,AndtbackaR, Randall RL Scaife CL, Hunt KK, Prieto VG, Raymond AK, Zhang W, Trent JC, Benjamin RS, Frazier ML. Evolution from Heterozygous to Homozygous KIT Mutation in Gastrointestinal Stromal Tumor Correlates with the Mechanism of Mitotic Nondisjunction and Significant Tumor Progression. Modern Pathology. In press. [abstract]
Randall RL, Aoki SK, Olson PR, Bott SI. Complications of cemented long-stem hip arthroplasties in metastatic bone disease. Clin Orthop Relat Res. 2006 Feb;443:287-95. [abstract], [fulltext] (UofU only).
Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res. 2006 Mar;24(3):474-80. [abstract], [fulltext] (UofU only).
Toy PC, France J, Randall RL, Neel MD, Shorr RI, Heck RK. Reconstruction of noncontained distal femoral defects with polymethylmethacrylate and crossed-screw augmentation: a biomechanical study. J Bone Joint Surg Am. 2006 Jan;88(1):171-8. [abstract], [full-text] (UofU only).
Blandford MC, Barr FG, Lynch JC, Randall RL, Qualman SJ, Keller C. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2006 Mar;46(3):329-38. [abstract].
Randall RL, Schabel KL, Hitchcock Y, Joyner DE, Albritton KH. Diagnosis and management of synovial sarcoma. Curr Treat Options Oncol. 2005 Nov;6(6):449-59. [abstract].
